The drugmaker plans to add two new production lines to the plant. One is slated to be done by fall, and the other by early 2022. The expansion will make it easier to produce Moderna’s COVID-19 vaccine and booster shots, should they become necessary to increase waning immunity levels or protect against coronavirus variants in coming years.
Moderna is also expanding its manufacturing capacity internationally, seeking to roughly triple its annual global production to about 3 billion vaccine doses in 2022.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
